Back to Agenda
Session 1: Key Notes: Are We on the Right Track?
Session Chair(s)
Margaret Anne Walters
Deputy EU Qualified Person for Pharmacovigilance
Merck, Sharp & Dohme Ltd, United Kingdom
The oversight of how drugs benefit and expose patients to risk is changing dramatically, driven by legislation, new therapies, unprecedented access to information and new unexpected challenges. A QPPV has to understand these forces, think creatively and be adaptable, to ensure industry manages their medicines and protects patients whilst ensuring optimal access and benefit to treatment.
Speaker(s)
Approaching Change as an Opportunity
Heather Bewers
Change Is An Opportunity Limited, United Kingdom
Director
Pharmacovigilance in the next 5 years, The Industry Vision
Vicki Edwards, RPh
Abbvie, United Kingdom
Vice President, Pharmacovigilance Excellence and International QPPV
Managing Sudden Change - Experience with a Cyber Attack
Janet Hormbrey, DrMed, MRCP, MSc, FFPM
Merck & Co, Inc., United States
AVP Global Pharmacovigilance
Have an account?